全文获取类型
收费全文 | 267篇 |
免费 | 6篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 2篇 |
妇产科学 | 63篇 |
基础医学 | 15篇 |
口腔科学 | 3篇 |
临床医学 | 19篇 |
内科学 | 14篇 |
皮肤病学 | 5篇 |
神经病学 | 11篇 |
特种医学 | 5篇 |
外科学 | 37篇 |
综合类 | 7篇 |
预防医学 | 9篇 |
眼科学 | 2篇 |
药学 | 22篇 |
肿瘤学 | 70篇 |
出版年
2021年 | 4篇 |
2019年 | 2篇 |
2018年 | 2篇 |
2017年 | 2篇 |
2016年 | 2篇 |
2015年 | 5篇 |
2014年 | 11篇 |
2013年 | 9篇 |
2012年 | 14篇 |
2011年 | 15篇 |
2010年 | 4篇 |
2009年 | 6篇 |
2008年 | 14篇 |
2007年 | 39篇 |
2006年 | 11篇 |
2005年 | 18篇 |
2004年 | 6篇 |
2003年 | 7篇 |
2002年 | 10篇 |
2001年 | 8篇 |
2000年 | 7篇 |
1999年 | 12篇 |
1998年 | 2篇 |
1997年 | 6篇 |
1996年 | 8篇 |
1994年 | 5篇 |
1991年 | 3篇 |
1990年 | 6篇 |
1988年 | 2篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1980年 | 3篇 |
1979年 | 10篇 |
1978年 | 2篇 |
1973年 | 1篇 |
1972年 | 4篇 |
1971年 | 1篇 |
1970年 | 2篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1967年 | 1篇 |
1966年 | 2篇 |
1965年 | 1篇 |
1963年 | 1篇 |
1948年 | 1篇 |
1942年 | 2篇 |
1941年 | 1篇 |
1939年 | 2篇 |
1937年 | 1篇 |
1936年 | 1篇 |
排序方式: 共有298条查询结果,搜索用时 15 毫秒
1.
肩、肘关节外科新进展 总被引:1,自引:0,他引:1
肩关节(Shoulder)
旋转袖(Rotator Cuff)
基础研究(Basic Science)
Zuckerman讨论了软骨诱导形态发生蛋白-2(cartilagederived morphogenetic protein-2,CDMP-2)的早期工作。在鼠肌腱修复中,4周时CDMP-2治疗组的修复强度高于未治疗组。Dines讨论了关于血小板衍生生长因子(platelet—derived growth factor,PDGF)和胰岛素样生长因子-1(insulin-like growth factor-1,IGF-1)最初的研究观察。 相似文献
2.
3.
Lyznicki JM Karlan MS Khan MK 《Journal of occupational and environmental medicine / American College of Occupational and Environmental Medicine》1999,41(3):140-143
This report responds to a resolution that asked the American Medical Association (AMA) to take action to reduce potential health risks from the use of methylcyclopentadienyl manganese tricarbonyl (MMT) in gasoline. Information for this report was derived from a search of the MEDLINE database and references listed in pertinent articles, as well as through communications with medical and public health experts. Based on this information, the AMA Council on Scientific Affairs determined that there is insufficient scientific evidence to assess the public health impact of MMT use. While limited evidence indicates that general-population exposures to manganese from the use of MMT in gasoline are low, more research is needed to determine possible health effects from long-term, low-dose exposures to MMT and its combustion products. Until such data are available, educational and informational strategies should be developed to improve public awareness of the health and environmental issues surrounding MMT use. 相似文献
4.
Lancaster JM Powell CB Kauff ND Cass I Chen LM Lu KH Mutch DG Berchuck A Karlan BY Herzog TJ;Society of Gynecologic Oncologists Education Committee 《Gynecologic oncology》2007,107(2):159-162
Women with germline mutations in the cancer susceptibility genes, BRCA1 or BRCA2, associated with Hereditary Breast/Ovarian Cancer syndrome, have up to an 85% lifetime risk of breast cancer and up to a 46% lifetime risk ovarian cancer. Similarly, women with mutations in the DNA mismatch repair genes, MLH1, MSH2 or MSH6, associated with the Lynch/Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome, have up to a 40-60% lifetime risk of both endometrial and colorectal cancer as well as a 9-12% lifetime risk of ovarian cancer. Genetic risk assessment enables physicians to provide individualized evaluation of the likelihood of having one of these gynecologic cancer predisposition syndromes, as well the opportunity to provide tailored screening and prevention strategies such as surveillance, chemoprevention, and prophylactic surgery that may reduce the morbidity and mortality associated with these syndromes. Hereditary cancer risk assessment is a process that includes assessment of risk, education and counseling conducted by a provider with expertise in cancer genetics, and may include genetic testing after appropriate consent is obtained. This commentary provides guidance on identification of patients who may benefit from hereditary cancer risk assessment for Hereditary Breast/Ovarian Cancer and the Lynch/Hereditary Non-Polyposis Colorectal Cancer syndrome. 相似文献
5.
Karam AK Santillan A Bristow RE Giuntoli R Gardner GJ Cass I Karlan BY Li AJ 《Gynecologic oncology》2007,104(2):377-380
OBJECTIVES: Studies of tertiary cytoreductive surgery (TCS) in recurrent epithelial ovarian cancer are limited, and appropriate patient selection remains a clinical challenge. We sought to evaluate the impact of TCS on survival and to determine predictors of optimal tertiary resection. METHODS: Between January 1997 and July 2004, 47 women with recurrent epithelial ovarian cancer underwent TCS at two institutions. All patients received initial platinum and taxane-based chemotherapy following primary cytoreductive surgery. Clinico-pathologic factors and survival were retrospectively abstracted from medical records. Optimal TCS was defined as microscopic residual disease. RESULTS: Thirty of 47 (64%) patients underwent optimal TCS. Size of tumor implants<5 cm on preoperative imaging was the only significant predictor of achieving optimal TCS. Overall survival after TCS was statistically longer in patients with microscopic versus macroscopic residual disease (24 versus 16 months, p=0.03). After controlling for age, time to progression and optimal TCS, only the presence of diffuse disease at tertiary exploration remained a significant poor predictor of survival. However, in a cohort of patients with limited disease implants, multivariate analysis indicated that optimal TCS retained prognostic significance as a positive predictor of survival. Twelve patients (26%) experienced severe postoperative complications, including six with pulmonary embolism, four with fistulae and two with postoperative myocardial infarctions. CONCLUSIONS: Size of disease implants on preoperative imaging may guide the selection of candidates for TCS. In those patients with limited disease implants at laparotomy, optimal TCS is associated with improved survival. 相似文献
6.
目的:巨细胞病毒感染是器官移植后的一个严重并发症,回顾性分析肝移植术后患者巨细胞病毒感染的诊断和防治方法.方法:①回顾分析2005-05/2006-08解放军总医院第二附属医院全军器官移植中心收治的19例肝移植受者的临床资料,供者均为健康献肝者.供者、受者对治疗方案均知情同意,且得到医院伦理道德委员会批准.②术后1个月检测1次巨细胞病毒血清抗体,预防和治疗巨细胞病毒感染均采用静脉注射更昔洛韦.术后采用三联免疫抑制疗法,根据术后血药浓度及肝功能改变调整免疫抑制药物用量.③采用酶联免疫吸附法检测患者血中巨细胞病毒抗体巨细胞病毒IgG、巨细胞病毒IgM.结果:19例受者中6例发生巨细胞病毒感染,均无临床症状,并全部治愈.结论:更昔洛韦能够有效治疗肝移植术后巨细胞病毒感染.积极预防、早期治疗肝移植术后患者巨细胞病毒感染是治疗成功的关键. 相似文献
7.
Joanne Kotsopoulos Parviz Ghadirian Ahmed El-Sohemy Henry T Lynch Carrie Snyder Mary Daly Susan Domchek Susan Randall Beth Karlan Phil Zhang Shiyu Zhang Ping Sun Steven A Narod 《Cancer epidemiology, biomarkers & prevention》2007,16(5):912-916
We have recently reported that, among BRCA1 mutation carriers, the consumption of caffeinated coffee was associated with a significant reduction in breast cancer risk. Because the metabolism of caffeine is primarily by CYP1A2, we examined whether or not the CYP1A2 genotype modifies the association between a history of coffee consumption and the risk of breast cancer. A common A to C polymorphism in the CYP1A2 gene is associated with decreased enzyme inducibility and impaired caffeine metabolism. Information regarding coffee consumption habits and the CYP1A2 genotype was available for 411 BRCA1 mutation carriers (170 cases and 241 controls). We estimated the odds ratios (ORs) and 95% confidence intervals (95% CIs) for breast cancer associated with the CYP1A2 genotype and a history of coffee consumption before age 35, adjusting for potential confounders. The CYP1A2 genotype did not affect breast cancer risk. Among women with at least one variant C allele (AC or CC), those who consumed coffee had a 64% reduction in breast cancer risk, compared with women who never consumed coffee (OR, 0.36; 95% CI, 0.18-0.73). A significant protective effect of coffee consumption was not observed among women with the CYP1A2 AA genotype (OR, 0.93; 95% CI, 0.49-1.77). Similar results were obtained when the analysis was restricted to caffeinated coffee. This study suggests that caffeine protects against breast cancer in women with a BRCA1 mutation and illustrates the importance of integrating individual genetic variability when assessing diet-disease associations. 相似文献
8.
Overexpression of HER-2/neu, a 185-kDa tyrosine kinase growth factor receptor, in human ovarian cancers has been correlated with a poor prognosis for survival of the disease. Previous studies have demonstrated that dexamethasone (Dex) induces a dose-dependent increase in HER-2/neu mRNA levels in the ovarian cancer cell line SK-OV-3 by stabilizing the HER-2/neu message. We extended these studies to test whether estrogen (Es), progesterone (Pr), and Dex were capable of regulating HER-2/neu mRNA levels in the human ovarian cancer cell lines NIH:OVCAR-3, SW 626, OVCA 433, and Caov-3. Southern blotting demonstrated that all four cell lines contained a single copy of the 12.5-kb HER-2/neu gene. Blotting techniques demonstrated low to barely detectable levels of HER-2/neu mRNA and protein in these cell lines. To determine whether steroids regulated HER-2/neu expression, all four ovarian cancer cell lines were cultured in the presence of 1 × 10-7M Es, Pr, or Dex and Northern blotting was completed. Unlike SK-OV-3 cells, the cell lines tested did not respond to the steroid treatments with alterations in their HER-2/neu mRNA levels. In conclusion, neither Es, Pr, nor Dex regulates HER-2/neu mRNA levels in NIH:OVCAR-3, SW 626, OVCA 433, and Caov-3 ovarian cancer cells. Future therapeutic manipulations of HER-2/neu should not involve hormonal intervention. 相似文献
9.
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer 总被引:4,自引:0,他引:4
Buller RE Runnebaum IB Karlan BY Horowitz JA Shahin M Buekers T Petrauskas S Kreienberg R Slamon D Pegram M 《Cancer gene therapy》2002,9(7):553-566
PURPOSE: To determine the safety, gene transfer, host immune response, and pharmacokinetics of a replication-deficient adenovirus encoding human, recombinant, wild-type p53 (SCH 58500) delivered into the peritoneal cavity (i.p.) alone and sequentially in combination with platinum-based chemotherapy, of patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer containing aberrant or mutant p53. METHODS: SCH 58500 was administered i.p. to three groups of patients with heavily pretreated recurrent disease. Group 1 (n=17) received a single dose of SCH 58500 escalated from 7.5 x 10(10) to 7.5 x 10(12) particles. Group 2 (n=9) received two or three doses of SCH 58500 given alone for one cycle, and then with chemotherapy for two cycles. The SCH 58500 dose was further escalated to 2.5 x 10(13) particles/dose in group 2. A third group (n=15) received a 5-day regimen of SCH 58500 given at 7.5 x 10(13) particles/dose per day i.p. alone for cycle 1 and then with intravenous carboplatin/paclitaxel chemotherapy for cycles 2 and 3. RESULTS: No dose-limiting toxicity resulted from the delivery of 236/287 (82.2%) planned doses of SCH 58500. Fever, hypotension abdominal complaints, nausea, and vomiting were the most common adverse events. Vector-specific transgene expression in tumor was documented by RT-PCR in cells from both ascitic fluid and tissue biopsies. Despite marked increases in serum adenoviral antibody titers, transgene expression was measurable in 17 of 20 samples obtained after two or three cycles of SCH 58500. Vector was detectable in peritoneal fluid by 24 hours and persisted for as long as 7 days whereas none was detected in urine or stool. There was poor correlation between CT scans and CA125 responses. CA125 responses, defined as a greater than 50% decrement in serum CA125 from baseline, were documented in 8 of 16 women who completed three cycles of the multidose regimen. CONCLUSION: CT scans are not a valid measure of response to i.p. SCH 58500 due to extensive adenoviral-induced inflammatory changes. Intraperitoneal SCH 58500 is safe, well tolerated, and combined with platinum-based chemotherapy can be associated with a significant reduction of serum CA125 in heavily pretreated patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. 相似文献
10.
Gene expression in epithelial ovarian carcinoma 总被引:1,自引:0,他引:1